Swiss National Bank Alx Oncology Holdings Inc Transaction History

Swiss National Bank

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 08, 2024	BUY	$5.84 - $17.56 $30,368 - $91,312	5,200 Added 11.76%	49,400 $297,000
Q1 2024 May 07, 2024	BUY	$10.95 - $16.79 $483,989 - $742,118	44,200 New	44,200 $492,000
Q1 2023 May 10, 2023	SELL	$4.52 - $11.71 $15,819 - $40,985	-3,500 Reduced 8.14%	39,500 $178,000
Q2 2022 Aug 09, 2022	BUY	$5.89 - $19.46 $140,182 - $463,148	23,800 Added 123.96%	43,000 $348,000
Q1 2022 May 09, 2022	BUY	$13.65 - $22.06 $20,475 - $33,090	1,500 Added 8.47%	19,200 $324,000
Q2 2021 Aug 06, 2021	SELL	$52.2 - $75.23 $26,100 - $37,615	-500 Reduced 2.75%	17,700 $968,000
Q1 2021 May 07, 2021	BUY	$62.84 - $87.68 $94,260 - $131,520	1,500 Added 8.98%	18,200 $1.34 Million
Q4 2020 Feb 05, 2021	BUY	$34.11 - $112.26 $569,637 - $1.87 Million	16,700 New	16,700 $1.44 Million

39.6M

134K

17.4K

Ticker ALXO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,747,100
Market Cap $42.4M
Description
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hod...

Get notified when there are updates to the investment portfolio of Swiss National Bank, based on Form 13F filings with the SEC.

Stay updated on Swiss National Bank with notifications on news.